ImmuCell (ICCC) vs Neogen (NEOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmuCell (ICCC) has outperformed Neogen (NEOG) over the past year, gaining 133.3% versus a gain of 84.4%. Over five years, ICCC leads with a +18.7% price change compared with -74.4% for NEOG. Neogen is the larger company by market cap ($2.30 billion vs $99.3 million), about 23.2 times the size, while ImmuCell is growing revenue faster (+4.3% vs -2.7%).
Neogen converts more of its revenue into profit, with a net margin of -0.9% versus -3.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | NEOG |
|---|---|---|
| Share price | $10.92 | $10.55 |
| Market cap | $99.28M | $2.30B |
| 1-day change | -2.41% | -2.76% |
| YTD return | +77.56% | +50.93% |
| 1-year return | +133.33% | +84.44% |
| 5-year return | +18.70% | -74.39% |
| P/E ratio (TTM) | 57.47 | — |
| Forward P/E | — | 23.44 |
| EPS (TTM) | $0.19 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.64M | $870.40M |
| Revenue growth (YoY) | +4.34% | -2.72% |
| Net income (latest FY) | $-1.04M | $-7.90M |
| Gross margin | 41.40% | 46.93% |
| Operating margin | 5.97% | -2.48% |
| Net margin | -3.76% | -0.91% |
| 52-week high | $12.10 | $14.26 |
| 52-week low | $4.67 | $5.60 |
| Distance from 52-week high | -9.75% | -26.02% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +32.70% |
| Average volume | 13.44K | 3.53M |
| Shares outstanding | 9.09M | 218.31M |
| Employees | 73 | 2,636 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neogen is about 23.2 times larger than ImmuCell by market value ($2.30B vs $99.28M).
- ICCC has outperformed NEOG by 48.9 percentage points over the past year.
- ImmuCell grew revenue faster in its latest fiscal year (+4.34% vs -2.72%).
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
ICCC vs NEOG FAQ
Which is bigger, ImmuCell or Neogen?
Neogen (NEOG) is larger, with a market capitalization of $2.30B compared with $99.28M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or NEOG?
ICCC returned +133.33% over the past 12 months, compared with +84.44% for NEOG (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Neogen in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.